Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $32.65, marking a -0.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 5.98%.

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds ...

Climate change is rapidly altering the agricultural landscape, leaving farmers scrambling to adjust. As temperatures rise, ...

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) ...

Collaborative research defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation. The method, ...

A recent study showcases the power of CRISPR gene editing to significantly boost the production of resveratrol, a ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.